HC Wainwright Issues Pessimistic Forecast for Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target lowered by HC Wainwright from $22.00 to $12.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other equities analysts have also recently weighed in on the stock. Brookline Capital Management initiated coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock. Truist Financial dropped their target price on shares of Y-mAbs Therapeutics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Morgan Stanley dropped their target price on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Bank of America dropped their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Finally, Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $18.30.

Y-mAbs Therapeutics Price Performance

YMAB stock opened at $5.00 on Friday. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $17.78. The stock has a market capitalization of $226.09 million, a PE ratio of -9.26 and a beta of 0.65. The company’s 50-day moving average is $5.71 and its 200-day moving average is $9.83.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. During the same period in the previous year, the business posted ($0.02) EPS. On average, analysts anticipate that Y-mAbs Therapeutics will post -0.65 earnings per share for the current fiscal year.

Insider Transactions at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the completion of the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. The trade was a 5.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Paradigm Biocapital Advisors LP grew its stake in Y-mAbs Therapeutics by 3.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after buying an additional 150,000 shares in the last quarter. Acorn Capital Advisors LLC purchased a new position in Y-mAbs Therapeutics in the 4th quarter valued at approximately $22,408,000. Caligan Partners LP grew its stake in Y-mAbs Therapeutics by 47.9% in the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock valued at $13,843,000 after buying an additional 572,729 shares in the last quarter. State Street Corp grew its stake in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock valued at $15,909,000 after buying an additional 405,169 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Y-mAbs Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock valued at $6,440,000 after purchasing an additional 8,820 shares during the period. 70.85% of the stock is currently owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.